Novo Nordisk Q2 Adjusted Operating Profit DKK 33.39B; Raises Outlook
Novo Nordisk reported Q2 2026 adjusted operating profit of DKK 33.39 billion, an 11% increase at constant exchange rates (CER), and adjusted sales of DKK 78.49 billion, up 7% at CER. The company raised its full-year 2026 outlook for adjusted sales and operating profit growth to 0% to -6% at CER, driven by increased expectations for GLP-1 product sales. Key commercial highlights include strong uptake of Wegovy® pill in the US and its launch in the UAE and UK, alongside EMA approvals for Wegovy® pill and Wegovy® 7.2 mg single-dose pen. However, the company recorded DKK 6.3 billion in non-cash impairment charges, including DKK 4.0 billion for monlunabant, and the ZEUS phase 3 trial for ziltivekimab failed to meet its primary endpoint.
Key Highlights
- Q2 2026 adjusted operating profit increased 11% at CER to DKK 33.39 billion.
- Q2 2026 adjusted sales grew 7% at CER to DKK 78.49 billion.
- Full-year 2026 adjusted sales and operating profit outlook raised to 0% to -6% at CER.
- Wegovy® pill Q2 sales reached DKK 3.22 billion; US weekly prescriptions exceeded 265,000.
- Total Obesity care adjusted sales increased 16% at CER to DKK 23.15 billion in Q2.
- Non-cash impairment charges of DKK 6.3 billion recorded in Q2, including DKK 4.0 billion for monlunabant.
- The ZEUS phase 3 trial for ziltivekimab in cardiovascular disease did not meet its primary endpoint.
- Wegovy® pill and Wegovy® 7.2 mg single-dose pen received EMA approval in July.
Price Impact
More from NVO